{"created":"2023-07-27T06:29:47.628847+00:00","id":14555,"links":{},"metadata":{"_buckets":{"deposit":"e0ce2150-0dee-4b06-bc67-4ca7b06a5fe8"},"_deposit":{"created_by":3,"id":"14555","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"14555"},"status":"published"},"_oai":{"id":"oai:kanazawa-u.repo.nii.ac.jp:00014555","sets":["1132:1133:1134"]},"author_link":["25646","22592","25648","514","71","25647"],"item_4_biblio_info_8":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2011-06-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"6","bibliographicPageEnd":"869","bibliographicPageStart":"863","bibliographicVolumeNumber":"46","bibliographic_titles":[{"bibliographic_title":"Bone Marrow Transplantation"}]}]},"item_4_description_21":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Human herpesvirus-6 (HHV-6) is a major cause of limbic encephalitis with a dismal prognosis after allogeneic hematopoietic SCT (HSCT). A prospective, multicenter study was conducted to assess the safety and efficacy of preemptive therapy with foscarnet sodium (PFA) for the prevention of HHV-6 encephalitis. Plasma HHV-6 DNA was measured thrice weekly from day 7 until day 36 after umbilical cord blood transplantation (UCBT) or HSCT from HLA-haploidentical relatives. PFA, 90 mg/kg/day, was started when HHV-6 DNA exceeded 5 × 102 copies/mL. Mild and transient adverse events were associated with PFA in 7 of 8 patients. Twelve of 15 UCBT recipients became positive for HHV-6 DNAemia, defined by greater than 1 × 102 copies/mL of HHV-6 DNA in plasma. The virus exceeded 5 × 102 copies/mL in seven patients, whereas none of the five HLA-haploidentical HSCT recipients became positive. One patient developed mild limbic encephalitis just after initial PFA administration. Preemptive PFA therapy is safe, but as HHV-6 DNAemia can abruptly develop before neutrophil engraftment in UCBT recipients, prophylactic PFA administration from day 7 or earlier after UCBT may be needed.Bone Marrow Transplantation advance online publication, 13 September 2010; doi:10.1038/bmt.2010.201.","subitem_description_type":"Abstract"}]},"item_4_description_5":{"attribute_name":"提供者所属","attribute_value_mlt":[{"subitem_description":"金沢大学医薬保健研究域医学系 　　","subitem_description_type":"Other"},{"subitem_description":"東京都立大塚病院　血液内科（輸血科）","subitem_description_type":"Other"}]},"item_4_publisher_17":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Nature Publishing Group"}]},"item_4_relation_12":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1038/bmt.2010.201","subitem_relation_type_select":"DOI"}}]},"item_4_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AA10673987","subitem_source_identifier_type":"NCID"}]},"item_4_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0268-3369","subitem_source_identifier_type":"ISSN"}]},"item_4_version_type_25":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Ishiyama, Ken"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Katagiri, Takamasa"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"Hoshino, Takumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yoshida, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Yamaguchi, Masaki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nakao, Shinji"}],"nameIdentifiers":[{},{},{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-10-03"}],"displaytype":"detail","filename":"ME-PR-ISHIYAMA-K-863BMT.pdf","filesize":[{"value":"310.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"ME-PR-ISHIYAMA-K-863BMT.pdf","url":"https://kanazawa-u.repo.nii.ac.jp/record/14555/files/ME-PR-ISHIYAMA-K-863BMT.pdf"},"version_id":"0931343f-4bfd-4c18-be12-0b4202b9e715"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT"}]},"item_type_id":"4","owner":"3","path":["1134"],"pubdate":{"attribute_name":"公開日","attribute_value":"2017-10-03"},"publish_date":"2017-10-03","publish_status":"0","recid":"14555","relation_version_is_last":true,"title":["Preemptive therapy of human herpesvirus-6 encephalitis with foscarnet sodium for high-risk patients after hematopoietic SCT"],"weko_creator_id":"3","weko_shared_id":-1},"updated":"2023-07-28T00:45:19.014199+00:00"}